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Abstract
Recent findings show that cerium oxide (CeO2) nanoparticles may undergo in vivo-induced
size transformation with the formation of smaller particles that could result in a higher trans-
location following pulmonary exposure compared to virtually insoluble particles, like titanium
dioxide (TiO2). Therefore, we compared liver deposition of CeO2 and TiO2 nanoparticles of
similar primary sizes 1, 28 or 180 days after intratracheal instillation of 162 μg of NPs in
female C57BL/6 mice. Mice exposed to 162 μg CeO2 or TiO2 nanoparticles by intravenous
injection or oral gavage were included as reference groups to assess the amount of NPs
that reach the liver bypassing the lungs and the translocation of NPs from the gastrointesti-
nal tract to the liver, respectively. Pulmonary deposited CeO2 nanoparticles were detected
in the liver 28 and 180 days post-exposure and TiO2 nanoparticles 180 days post-exposure
as determined by darkfield imaging and by the quantification of Ce and Ti mass concentra-
tion by inductively coupled plasma-mass spectrometry (ICP-MS). Ce and Ti concentrations
increased over time and 180 days post-exposure the translocation to the liver was 2.87 ±
3.37% and 1.24 ± 1.98% of the initial pulmonary dose, respectively. Single particle ICP-MS
showed that the size of CeO2 nanoparticles in both lung and liver tissue decreased over
time. No nanoparticles were detected in the liver following oral gavage. Our results suggest
that pulmonary deposited CeO2 and TiO2 nanoparticles translocate to the liver with similar
calculated translocation rates despite their different chemical composition and shape. The
observed particle size distributions of CeO2 nanoparticles indicate in vivo processing over
time both in lung and liver. The fact that no particles were detected in the liver following oral
exposure showed that direct translocation of nanoparticles from lung to the systemic circula-
tion was the most important route of translocation for pulmonary deposited particles.
PLOS ONE | https://doi.org/10.1371/journal.pone.0202477 August 20, 2018 1 / 22
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Modrzynska J, Berthing T, Ravn-Haren G,
Kling K, Mortensen A, Rasmussen RR, et al. (2018)
In vivo-induced size transformation of cerium oxide
nanoparticles in both lung and liver does not affect
long-term hepatic accumulation following
pulmonary exposure. PLoS ONE 13(8): e0202477.
https://doi.org/10.1371/journal.pone.0202477
Editor: Bing Xu, Brandeis University, UNITED
STATES
Received: May 17, 2018
Accepted: August 4, 2018
Published: August 20, 2018
Copyright: © 2018 Modrzynska et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The project was supported by the Danish
Centre for Nanosafety (grant no. 20110092173-3)
from the Danish Working Environment Research
Foundation. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Introduction
Unique properties exhibited by nanoparticles (NPs) such as small size, large surface area and
high reactivity as compared to fine particles or bulk material has led to the development of a
wide range of industrial applications of NPs. NPs can be used in various day-to-day consumer
products including cosmetics, electronics, sporting goods, paints, lacquers and tires. They
could also serve as food additives and cosmetics Therefore, several portals of entry and differ-
ent target tissues exist [1–4]. Understanding the deposition fate of NPs after administration to
the body is a crucial part of hazard evaluation of nanomaterials.
Both cerium oxide (CeO2) and titanium dioxide (TiO2) NPs have versatile applications and
are widely used in everyday products. CeO2 can be used as an abrasive agent for chemical-
mechanical planarization of advanced integrated circuits [5], polishing agent for glass mirrors,
television tubes and ophthalmic lenses [6], oxygen sensor [7], diesel fuel catalyst to improve
combustion and therefore reduce consumption of the fuels [6] and in solid oxide fuel cells [8].
TiO2 is widely used as white pigment due to its brightness and high refractive index [9] and is
therefore utilized in paints, coatings, cosmetics (sunscreen, toothpaste) and in pharmaceuticals
[10]. Moreover, it has been approved as a food additive in Europe (also known as E171) used
in candy and chewing gum [11].
Inhalation is the most relevant exposure route for occupational exposure to NPs. It has
been previously observed that particles deposited in the lungs after inhalation or intratra-
cheal instillation are cleared from the respiratory tract by various clearance mechanisms and
various routes. Inhaled nanosized particles, deposited preferentially in the alveolar region,
are cleared mainly by macrophage-mediated phagocytosis. Internalized particles gradually
moved toward the mucociliary escalator in the upper airways [12]. Once the particles reach
the bronchi, they are transported up into the pharynx and swallowed, causing gastrointesti-
nal tract (GIT) exposure [2,13–16]. Nonetheless, the uptake of NPs by the GIT has been
shown to be very low [9,15,17–19]. Inhaled NPs may also migrate across the alveolar epithe-
lium, through interstitium, access systemic circulation directly or via lymphatic vessels and
accumulate in the liver and spleen [20–25]. Inconsistent results regarding the fraction of
ultrafine particles (UFP) that undergo extrapulmonary translocation and further deposition
in the secondary organs have been reported [14,25–27]. The degree of translocation is influ-
enced by various physicochemical properties like size, chemical composition, shape and elec-
trical charge [14,28].
The liver, among other reticuloendothelial organs, seems to be the major organ for accumu-
lation of insoluble particles such as metal NPs after accessing systemic circulation [29–33].
Translocated NPs reach the liver, and they have been shown to accumulate in the Kupffer cells,
which are specialized macrophages located in the liver [29,34,35]. The Kupffer cells constitute
the first line of the defense against xenobiotics. The clearance rate of NPs from Kupffer cells is
very slow. Thus, 90% of an injected gold NP (40 nm) dose was still detected in the liver tissue 6
months after exposure [36]. Previous studies indicate that pulmonary exposure to reactive NPs
is associated with genotoxic effect observed in the liver tissue [13,37–39].
Graham and colleagues [40] recently showed that hydro-thermally derived CeO2 NPs
undergo in vivo processing in the liver tissue over time. The originally cube-shaped CeO2 NPs
became highly fragmented and rounded along their edges ninety days after exposure. No NP
transformation was observed thirty days after exposure. Additionally, the accumulation of 1–3
nm crystallites in close proximity to the parental CeO2 NPs was observed. Dissolution of high-
energy edge sites was suggested as the underlying mechanism.
The aim of the present study was to evaluate extrapulmonary translocation of lung-de-
posited CeO2 and TiO2 and to assess whether the partial solubility of CeO2 affect hepatic
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accumulation. We also wanted to determine size distribution changes of long-term deposited
particles in the lung and liver tissue.
Materials and methods
Preparation of NP suspensions and characterization of exposure media
Powdered cerium dioxide (CeO2) was provided by Degussa-Quimidroga and powdered tita-
nium dioxide (TiO2) was provided by NanoAmor (Nanostructured & Amorphous Materials).
NP suspensions of 3.24 mg/ml were prepared in 2% mouse serum as described in [41,42].
TiO2 NPs have been shown to induce similar inflammatory responses when dispersed in nano-
pure water or 2% serum [43], suggesting that the serum was not immunogenic in the present
experimental set-up. 2% serum was chosen since dispersion in this vehicle resulted in stable
dispersion of nanosized aggregates. In short, stock suspensions of 3.24 mg/ml alongside con-
trol vehicle were sonicated for 15 min on ice, to prevent sample overheating, using a probe
sonicator operating at 100 W/22.5 kHz (Microson ultrasonic cell disruptor, XL-2000 Micro-
son™, Qsonica, LLC., equipped with disruptor horn with a diameter of 3.2 mm and maximum
peak-to-peak amplitude of 180 μm). The size distribution of each produced NP suspension
was determined by dynamic light scattering (Zetasizer Nano-ZS, Malvern Instruments, UK) as
described [38,44]. The refractive index and the index of absorption for the test materials were:
2.2 and 0.1, respectively, for CeO2, 2.903 and 0.1, respectively, for TiO2. Optical data for water
were used for the control vehicle.
Preparation and analysis of electron microscopy samples
Samples were dispersed on TEM (Transmission Electron Microscope) grids covered with holy
carbon foil according to a standard protocol for diameter and morphological analyses of nano-
material in SEM (Scanning Electron Microscope) and TEM. 0.2 mg of CeO2 and 0.5 mg of
TiO2 were dispersed in 8 ml of N-methyl 2-pyrrolidone and incubated for 10 min in an ultra-
sound bath. The dispersion was sonicated using a probe sonicator with a 13 mm probe tip for
10 min at 10% amplitude on ice. After sonication, 10 μL of sample was dispersed onto a TEM-
grid. The samples were dried in a vacuum chamber for 5 min. Afterwards samples were further
dried under red light (warming lamp) for 24 h.
Images were recorded at the ZEISS facility in Oberkochen, Germany by curtesy of Dr.
Xiong Liu, using a GeminiSEM 300 equipped with a STEM detector (ZEISS, Oberkochen, Ger-
many). Plasma cleaning was applied to the samples inside the microscope chamber, to derive a
better image quality.
Animal study
216 young adult C57BL/6 (B6JBOM-F) female mice were purchased from Taconic (Ry, Den-
mark) at 6 weeks of age and body weight (bw) of 17.5 ± 0.9 g (mean ± SD). Mice were acclima-
tized for 2 weeks before the beginning of the experiment. Upon delivery mice were randomly
divided into experimental groups and control groups (n = 9) and housed in polypropylene
cages (Type III with Tapvei bedding and enrichment–nesting material and den), 5 or 4 mice in
each, under the following conditions: 12 h light/12 h dark cycle, room temperature of
22˚C ± 1˚ and the relative humidity of 55% ± 5. Throughout the whole experiment mice were
given a standard pellet diet (Altromin No. 1324) and citric acid acidified tap water (to avoid
microbiological contamination of drinking water), both ad libitum. All mice were weighted
weekly and food intake was noted. For 6 months exposure groups, bw was recorded once in 2
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weeks intervals after day 28. Mice were observed daily for any sign of abnormalities in their
clinical appearance.
Mice were dosed a single dose of 162 μg of CeO2 or TiO2 NPs in 50 μl of 2% serum in nano-
pure water by intratracheal instillation (IT), oral gavage (PO) or intravenous injection (IV).
Control mice received 50 μl of 2% serum. The dose corresponds to the pulmonary deposition
during 13 8-h working days at the Danish occupational exposure limit of 10 mg/m3 for TiO2
assuming 9% alveolar deposition [45,46]. Prior to the administration of NP suspension by
either intravenous injection or intratracheal instillation animals were anaesthetized by subcu-
taneous injection in the neck with 0.5 ml/100g of Hypnorm1 (Fentanyl citrate 0.315 mg/ml
and Fluanisone 10 mg/ml, Nomeco) and Dormicum1 (Midazolam 5 mg/ml, Roche) diluted
1:1 by volume in sterile water and mixed. Orally administered mice were not anaesthetized
during dosing. Intratracheal instillation was performed as previously described [46]. In brief,
mice were placed on a 40˚ slope (upside down, with the head towards the floor) and a diode
lamp was located on the larynx for a better visualization. A small spatula was used to press the
tongue towards the lower jaw and the 22 GA BD Insyte catheters (Becton Dickinson, Utah,
USA) with a shortened needle was used to intubate the trachea. A volume of 50 μl followed by
200 μl air in a 250 μl SGE glass syringe (250F-LT-GT, MicroLab, Aarhus, Denmark) was
instilled. In order not to block the airways and to assure that the NP suspension maintains in
the lung, mice were placed back into a vertical position with the head up as soon as the catheter
was removed. For oral gavage, mice were gently restrained in a vertical position to immobilize
the head and the gavage needle (0.9 x 38 mm, NOVA-SCB, Sweden) was inserted into the
esophagus and further toward the stomach. For intravenous injection anaesthetized mice were
restrained in a Plexiglas restraining tube. A tail-vein injection was performed with a 0.4 × 20
mm needle (Terumo Europe, n.v. 3001, Leuven, Belgium). After intratracheal instillation,
gavage and intravenous injection animals were transferred back to their cages, heated with a
heating lamp and/or warming blanket and monitored until they fully recovered from anesthe-
sia. The animals did not show any adverse effects caused by the administration procedure. Eth-
ical approval was given by the Danish Animal Experiments Inspectorate (Permission 2012-15-
2934-00089 C6) and the specific experiment was approved and overseen by the Animal Wel-
fare Committee for Animal Care and Use of the National Food Institute, Technical University
of Denmark.
Necropsy and organ collection
After the exposure period– 1 day, 28 days or 180 days, animals were weighted and prepared
for necropsy. Mice were terminated by the overdose of Hypnorm–Dormicum mixture (0.5–
0.7 ml/100 g). The mice abdomen and thorax were opened and all macroscopic abnormalities
were noted in the autopsy report. Pieces of liver and lung (right caudal lobe) tissue for further
ICP-MS analysis were collected and snapped frozen in cryotubes (NUNC) in liquid nitrogen
and stored at—80˚C until used. A piece of liver tissue was fixated in 4% neutral buffered for-
malin for 24 hours and embedded in paraffin blocks on the next day. Lungs were removed
intact, filled with formalin and submerged in 4% neutral buffered formalin. Liver and lungs tis-
sue sections of 3 μm thickness were cut and stained with hematoxylin and eosin for further
light and darkfield microscopy.
Enhanced darkfield microscopy
Cytoviva enhanced darkfield hyperspectral system (Auburn, AL, USA) was used to detect par-
ticles in liver and lung, by scanning histological sections at 40x magnification in enhanced
darkfield mode. Images were acquired at 40x and 100x using an Olympus BX 43 microscope
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with a Qimaging Retiga4000R camera. Uneven illumination in brightfield images was cor-
rected using ImageJ [47] and the Calculator Plus plugin via the formula: Corrected image =
(image / background)  255. The background image was a maximum projection of 3 back-
ground brightfield images without tissue.
Determination of mass concentration of Ce and Ti in mouse organs by
ICP-MS
The total mass concentration of cerium (Ce) and titanium (Ti) in animal tissues (liver and
lung) was determined by inductively coupled plasma-mass spectrometry (ICP-MS). Tissue
samples (100 mg for liver and 40 mg for lung) were taken from the same part of the lungs and
livers from each animal. Ultrapure water (18.2 mOcm at 21.5˚C) was obtained from a Milli-
pore Element apparatus (Millipore, Milford, MA, USA) and used throughout the work.
For analysis of Ce by ICP-MS, approximately 100 mg of the liver tissue was thawed, exactly
weighed, mixed with 1.5 ml of ultrapure water and homogenized using an Ultra Turrax
homogenizer (DI 25 Basic, Ika-Werke, Staufen, Germany) for 3 min at 8000 rpm. For Ti analy-
sis Ceramic Bead Tubes (Ø 1.4 mm, made of zirconium oxide, MoBio, Denmark) were used
for liver tissue homogenization to avoid potential release of Ti-containing particles from the
Ultra Turrax homogenizer. Approximately 100 mg of the liver tissue was thawed, exactly
weighed, mixed with 1.5 ml of ultrapure water and ceramic beads and subsequently homoge-
nized for 3 min using a Tissue Lyser (Qiagen, manufactured by Retsch). A volume of tissue
homogenate corresponding to 40 mg of tissue was transferred to disposable standard glass
vials (Wheaton1 15x46 mm, cap 13–425) and subsequently digested in a mixture of 0.250 ml
concentrated nitric acid (68% HNO3, PlasmaPure, SCP Science, Quebec, Canada) and 0.125
ml hydrogen peroxide (Suprapur, Merck, Darmstadt, Germany) in a microwave oven (Multi-
wave 3000, Anton Paar GmbH, Graz, Austria) equipped with a 64MG5 rotor at elevated tem-
perature and pressure (~ 140˚C; max. 20 bar). After digestion, ultrapure water was added to a
final sample weight of 3 g. Samples were further diluted 10- to 1000-fold with ultrapure water
prior to analysis. The rest of the Ce and Ti homogenate was stored at -20˚C for single particle
ICP-MS analysis. Approximately 40 mg of the lung tissue was prepared as described above
excluding the homogenization procedure.
The Ce mass concentration in the tissues was determined by using an iCAP Q ICP-MS
instrument (Thermo Fisher Scientific GmbH, Bremen, Germany) equipped with an ASX-520
autosampler (Cetac Technologies, Omaha, USA). Typical instrumental settings for the analysis
are given in Table 1. The concentration of Ce was quantified against an external calibration
curve prepared in 2% nitric acid from a Ce stock solution of 1000 μg/ml (SCP Science, Quebec,
Canada). To reduce carry-over, careful rinsing with 2% nitric acid between samples was
performed.
The Ti mass concentration in the tissues was determined by using an Agilent 8800 Triple
Quadrupole ICP-MS instrument (Agilent Technologies, California, USA) equipped with an
ASX-520 autosampler (Cetac Technologies, Omaha, USA). Typical instrumental settings for
the analysis are given in Table 1. The concentration of Ti was quantified against an external
calibration curve prepared in 2% nitric acid from Ti stock solution of 1.000 μg/ml (SCP Sci-
ence, Quebec, Canada) and with scandium (Sc) as an internal standard (stock solution of
1.000 μg/ml, SCP Science, Quebec, Canada). To reduce carry-over, careful rinsing with 2%
nitric acid between samples was performed.
Blank samples, laboratory duplicates and spiked samples were included in all analyses for
quality control. No suitable certified reference materials for CeO2 or TiO2 were available. The
limit of detection (LOD) in the liver tissue was the range of 39–112 ng/g for Ce and between
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539–852 ng/g for Ti. LOD in the lung tissue was estimated to be between 8–14 ng/g for Ce and
between 742 and 2192 ng/g for Ti. The LOD in tissues varied for the different sample types
due to different sample intake in the digestion step and the sample dilution prior to analysis.
Determination of size distribution of CeO2 NPs in mouse organs by
spICP-MS
A previously developed enzymatic digestion procedure was modified and applied [48]. Briefly,
a volume of liver homogenate which contained 25 mg of liver tissue or ~ 25 mg of unhomoge-
nized lung tissue was mixed with 3 ml of 3 mg/ml Proteinase K solution in 50 mM ammonium
bicarbonate buffer at pH 7.4, containing 5 mg/ml SDS and 0.2 mg/ml NaN3 as antimicrobial
agent and 1 ml of ultrapure water. The mixture was incubated over night at 40˚C in a water
bath under continuous stirring. As a blank sample, unexposed liver or lung tissue was
included. Prior to the spICP-MS measurement, samples were further diluted between 100-
and 50.000-fold with ultrapure water, depending on the Ce mass concentration measured by
conventional ICP-MS.
The iCAP Q ICP-MS instrument was used for spICP-MS analysis. Instrument settings are
given in Table 1. The peristaltic pump was set to 40 rpm for all experiments, which corre-
sponded to a sample flow rate of approximately 0.4 ml/min. This value was accurately deter-
mined daily by weighing the amount of water that was delivered by the peristaltic pump for 1
min. Ce mass calibration was achieved by analysis of a blank and five ionic Ce standards rang-
ing from 0.2 to 5.0 ng/l diluted from a certified solution in 100x diluted enzymatically digested
liver tissue. The 140Ce intensity for each solution was averaged from the entire length of the
analysis (180 s). To evaluate for possible instrumental drift over time the standards were ana-
lyzed at the beginning and the end of the analysis sequence. The nebulization efficiency of the
liquid samples through the sample introduction system was determined according to the “par-
ticle frequency” method [49] by the measurement of reference gold nanoparticle (AuNP) sus-
pension (RM 8013, National Institute of Standards and Technology, Gaithersburg (NIST),
MD, USA) with a known average particle diameter of 56 nm (based on the measurements by
transmission electron microscopy provided by NIST) and a gold mass concentration of
51.86 ± 0.64 μg/g (information value provided by NIST), diluted 106-times with ultrapure
water. The nebulization efficiency was calculated as the percentage of all Au NPs detected by
Table 1. Instrumental settings for ICP-MS analysis.
Parameter (unit) Ce analysis CeO2 single particle analysis Ti analysis
RF power (W) 1550 1550 1550
Plasma gas flow rate (l/min) 14 14 15
Nebulizer gas flow rate (ml/min) ~1.1 ~1.1 ~1.1
Auxiliary gas flow rate (ml/min) ~0.8 ~0.8 ~0.1
Cell gas flow rate (ml/min) n/a n/a 2 ml/min NH3/He (10/90)
+ 1 ml/min He
Monitored isotopes (m/z) 140Ce 140Ce, 197Au Q1! Q2 masses: 48! 150 (Ti);
45! 130 (Sc)
Dwell time (ms) 10 3 100
Nebulizer type Low-flow concentric nebulizer Low-flow concentric nebulizer Agilent MicroFlow (model no. G3139A-100)
Spray chamber type Cyclonic, Peltier-cooled (quartz) Cyclonic, Peltier-cooled (quartz) Scott double-pass, Peltier-cooled (quartz)
https://doi.org/10.1371/journal.pone.0202477.t001
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spICP-MS versus the theoretical (calculated) particle number in the introduced sample vol-
ume, derived from the TEM-based average size, the measured uptake rate and time of intro-
duction of the sample suspension into the ICP-MS instrument.
For each sample the 140Ce signal intensity was continuously monitored for 60 s or 180 s
which corresponded to 20,000 or 60,000 data points, respectively, when using 3 ms dwell time.
Following the analysis of each sample, ultrapure water was analyzed to illustrate if carry-over
from the previous measurement could be excluded. Intensity data were recorded by the
ICP-MS software and exported to Microsoft Excel 2010 for Windows (Microsoft Inc., WA,
USA) for further processing. Raw signal intensity data were plotted (in counts per second) ver-
sus number of events to create a signal distribution histogram. Very low signal intensities were
considered instrument background or for slightly higher intensity values dissolved cerium or
cerium clusters. An iterative algorithm was applied where “particle events” were distinguished
as outliers from the background/dissolved ion signal if the measured intensity was more than
five times the standard deviation of the whole data set as described by [50]. For each “particle
event”, the signal intensity was converted to Ce mass (per particle) based on the slope of the
calibration curve obtained with the ionic Ce standards multiplied with dwell time, sample flow
rate and nebulization efficiency. Finally, the Ce mass was converted to particle diameter by
assuming spherical particles of CeO2 (fraction of Ce 0.53) with densities of 7.132 g/cm
3.
Statistical analysis
All presented values are expressed as mean ± standard deviation of the mean (SD) unless stated
differently. One-way or two-way analysis of variance (ANOVA) was used to analyze the data
sets. In order to fulfil the normality and variance homogeneity criteria some variables were
logarithmically transformed. Non-normally distributed data were ranked before applying non-
parametric one-way or two-way ANOVA analysis. If the statistical significance was reached in
the ANOVA analysis, Tukey post-hoc multiple comparison test was used to test the differences
between the test groups. P-value of 0.05 was considered significant. All statistical analyses were
calculated using SAS 9.4 statistical software (SAS Institute Inc., Cary, NC, USA).
Results
Mortality
After administration of NPs mice were monitored daily for any signs of sickness or injury,
abnormalities in their general appearance as well as changes in their behavior. Among 216
mice used in the experiment, 3 unexpected deaths were reported during the up to 6 months
long post exposure period. These were one mouse from the PO 6 months CeO2 group, one
mouse from IV 28 days control group, one mouse was from IV 6 months TiO2 group. The
causes of death were not established and the mice were excluded from the experiment.
Physicochemical characterization of nanomaterials
The key physicochemical parameters of the studied nanomaterials have been previously pub-
lished [51–53] and are summarized in Table 2. Agglomerate size of particle suspensions was
determined using dynamic light scattering (DLS). The hydrodynamic number-based size dis-
tribution showed a single peak with the average diameter below 100 nm for both CeO2 and
TiO2 NP suspensions (Fig 1). Median particle diameters measured for CeO2 and TiO2 were 79
nm and 68 nm, respectively. Z-average and polydispersity index were 159.7 and 0.216, respec-
tively, for CeO2 and 125.9 and 0.122, respectively, for TiO2. For CeO2, the size distribution of
the particle suspension was additionally determined by spICP-MS (S1 Fig). The median
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diameter was around 50 nm. However, when the suspension was enzymatically treated, the
median diameter decreased to around 35 nm. TiO2 NPs were not characterized by spICP-MS
due to the relatively high size LOD of 50–60 nm for this type of NPs.
In STEM investigations, the CeO2 NPs appeared as aggregates of primary crystals (Fig 2A).
Images taken at high magnification in STEM mode (S2 Fig) showed that the size of primary
Table 2. Key physicochemical parameters of the tested nanomaterials.
CeO2 TiO2 (rutile)
Source Degussa/Quimidrogaa NanoAmorb
Product form Powder Powder
Primary particle size 13.0 ± 12.1 nma 10.5 nmb
Specific surface area 56.7 m2/ga 139.1 m2/gb
Particle density 7.29 g/cm3a 4.23 g/cm3c
aLevin et al. J Nanoparticle Res. 2015;17:1–13
bHalappanavar et al. Environ Mol Mutagen. 2015;56:245–264
cLide DR. CRC Handbook of Chemistry and Physics 84th ed. Boca Raton: CRC Press LLC; 2003.
https://doi.org/10.1371/journal.pone.0202477.t002
Fig 1. Size distributions of CeO2 and TiO2 particle suspensions obtained by DLS. CeO2 and TiO2 particles were suspended in 2% serum in nanopure water.
Intensity- and number-based size distributions are presented. The figure was adapted from [39].
https://doi.org/10.1371/journal.pone.0202477.g001
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particles varies from few nm up to several tens of nm. The aggregate size cannot be determined
from the images obtained. Particles regardless of size appeared cubic (fluorite structure, space
group Fm3m) however, the crystalline structure and phase of particles was not investigated in
the scope of this study. TiO2 NPs appeared as aggregates of primary crystals (Fig 2B). Images
taken at high magnification in STEM mode (results not shown) showed that the primary parti-
cles were nanorods with a length of 50 to 60 nm and a diameter of 10 to 15 nm.
Brightfield and enhanced darkfield microscopy of lung and liver tissues
Figs 3 and 4 show lung and liver sections, respectively, from mice intratracheally instilled with
a control vehicle (2% serum) or 162 μg/animal of CeO2 or TiO2 180 days post exposure. Lung
sections from mice exposed to CeO2 and TiO2 revealed presence of foreign material aggregates
in the pulmonary region, thus documenting successful pulmonary dosing. The aggregates
showed intense light scattering in enhanced darkfield (Fig 3B2 and 3C2, white arrowheads)
and had a brownish appearance in brightfield (Fig 3B1 and 3C1, black arrowheads). In the two
exposure groups, the foreign material was predominantly found in the alveolar region,
retained in macrophages, in the interstitium, and in the alveolar lumen (Fig 3B and 3C).
Sections of liver tissue were scanned for presence of foreign material. Liver sections from
mice exposed to CeO2 and TiO2 by intratracheal instillation revealed the presence of light scat-
tering aggregates of foreign material that were also visible in brightfield at high magnification.
The foreign material was predominantly found in sinusoids and there often close to nuclei,
which based on shape and location could be Kupffer cell nuclei (Fig 4B and 4C, white and
black arrowheads). In all groups, including vehicle controls, highly scattering material with a
different appearance (intensity, size or color) was occasionally found (example in Fig 4A,
arrowheads). The localization indicated artefacts from tissue preparation.
Following oral gavage, neither CeO2 nor TiO2 NPs could be detected in liver tissue (S3 Fig).
Biodistribution of NPs in the liver and lung tissue
The content of TiO2 and CeO2 in the liver and lung tissues was estimated by quantifying Ce
and Ti mass concentrations by inductively coupled plasma mass spectrometry (ICP-MS). Ce
concentrations in the liver were statistically significantly increased 28 and 180 days after intra-
tracheal exposure to CeO2 NPs when compared to the vehicle control (P 0.001 and
P 0.0001, respectively) and when compared to the PO exposed groups (P 0.0001 and
P 0.0001, respectively) (± A). Ti concentrations in the liver were statistically significantly
Fig 2. STEM images. CeO2 NPs (A) and TiO2 NPs (B).
https://doi.org/10.1371/journal.pone.0202477.g002
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Fig 3. Brightfield (1) and enhanced darkfield (2) microscopy images of H&E stained lung tissue. (A) From intratracheally instilled
mice that received a control vehicle, (B) 162 μg/animal of CeO2 or (C) TiO2 NPs at 180 days post exposure. In the lung sections from
mice exposed to CeO2 and TiO2 light scattering aggregates of foreign material were observed using enhanced darkfield microscopy (B2
and C2, respectively, white arrowheads). The aggregates exhibited a brownish appearance in brightfield (B1 and C1, black arrowheads).
https://doi.org/10.1371/journal.pone.0202477.g003
Fig 4. Brightfield (1) and enhanced darkfield (2) microscopy images of H&E stained liver tissue. (A) From intratracheally instilled mice that
received a control vehicle, (B) 162 μg/animal of CeO2 or (C) or TiO2 NPs at 180 days post-exposure. In the liver sections from mice exposed to CeO2 and
TiO2 foreign material aggregates were observed using enhanced darkfield microscopy, mainly in sinusoids and often close to small nuclei (B and C,
respectively, 2, 4 and 6, white arrowheads). The aggregates were not detectable in brightfield at 40x magnification (B1, C1), but exhibited a brownish
appearance at 100x magnification (B and C, 3 and 5, black arrowheads). Appearance of a typical artefact is shown (A, 3–4, arrowheads). Panels 3–6
correspond to the rectangular zones in panel 1–2 captured at higher magnification.
https://doi.org/10.1371/journal.pone.0202477.g004
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increased 180 days after intratracheal exposure to TiO2 NPs (P 0.05) when compared to the
vehicle control, but no statistically significant differences between IT and PO groups were
found at any of the analyzed time points (Fig 5B). The proportion of Ce or Ti that accumulated
in the liver 180 days post exposure for CeO2 and TiO2 was 2.87 ± 3.37% or 1.24 ± 1.98%
(mean ± SD), respectively, of the total lung-delivered Ce or Ti dose (based on a NP exposure
of 162 μg/lung) (Fig 6). The observed difference in the translocation was not statistically signif-
icant. No elevated Ti or Ce concentrations were detected in the livers from orally gavaged
mice (Fig 5A and 5B). The Ce and Ti concentrations in liver of vehicle-exposed mice were
below the LOD at all assessed time points.
After intratracheal instillation of CeO2 NPs, Ce concentrations in lung were statistically sig-
nificantly increased at all assessed time points (P 0.001 after day 1, P 0.0001 after day 28
and P 0.0001 after day 180) compared to vehicle control (S4 Fig). Ti concentrations in lung
after intratracheal instillation of TiO2 NPs were also statistically significantly increased at all
assessed time points (P 0.05 after day 1, P 0.001 after day 28, P 0.001 after day 180)
compared to vehicle control (S4 Fig). At day 1 and day 28 calculated CeO2 contents in the
lungs were statistically significantly different compared to TiO2 contents (P 0.05 and
P 0.05, respectively) (S4 Fig). The CeO2 and TiO2 contents were calculated by assuming that
all Ce or Ti was present in the form of CeO2 or TiO2 NPs, respectively. The Ce and Ti concen-
trations in the lungs of vehicle-exposed mice were below the LOD at all assessed time points.
Assessment of CeO2 NPs size distribution by single particle ICP-MS
The size distributions of CeO2 NPs in the liver and lung tissue were assessed by single particle
ICP- MS (spICP-MS). The determined sizes were mass-equivalent diameters (diameters of a
sphere having the same mass as the studied particle). The spICP-MS technique was used to
analyze CeO2 NPs in the size range between 18 and 150 nm. An upper size limit of 150 nm was
chosen because at higher particle sizes/masses, incomplete particle vaporisation and non-
Fig 5. Mass concentration of Ce (A) and Ti (B) in liver tissue. The concentrations were measured by ICP-MS following intratracheal
instillation and oral gavage of CeO2 and TiO2 NPs, respectively. Data are presented as mean + SD. An asterisk (
) denotes P 0.05, ()
P 0.001, () P< 0.0001 of Ce or Ti mass concentration in exposed groups compared to vehicle controls. Hashtags (###) denote
P< 0.001 and (####) P< 0.0001 of Ce mass concentration in intratracheally exposed group (IT) compared to orally exposed groups
(PO). LOD–Limit of detection.
https://doi.org/10.1371/journal.pone.0202477.g005
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linear detector responses can occur, leading to an underestimation of particle size and mass
[54]. Larger NPs (up to 670 nm), most likely aggregates, were detected in all tissue samples but
excluded from the quantification. However, on average only 0.6% and at maximum 1.6% of
the number of all detected particles was larger than 150 nm. Particles NPs smaller than 18 nm
were below the LOD. The size distribution of CeO2 NPs in lung tissue (Fig 7) 1 day after pul-
monary exposure was similar to the size distribution of the administered particles in 2% serum
when subjected to the same enzymatic treatment as the tissue samples. The median particle
diameter was 35 nm. 180 days post exposure, the size distribution of pulmonary particles
shifted towards smaller sizes with the median particle diameter decreasing from 35 nm (1 day)
to 25 nm (180 days). The mass recovery of Ce as 18–150 nm CeO2 NPs determined by
spICP-MS decreased significantly from 40% ± 28 (1 day, N = 6) to 6% ± 8% (180 days, N = 4)
of the total Ce concentration determined by ICP-MS. This was presumably due to the shift of
the size distribution to values below the size LOD (Table 3). CeO2 NPs frequency in the lung
tissue 1 day and 180 days following intratracheal instillation and normalized to the % of recov-
ery of Ce as 18–150 nm CeO2 NPs is presented in S5 Fig.
One day post exposure, the IV dosed particles residing in the liver had the same size distri-
bution as the dosed NPs (Fig 8). The particle size distributions were similar 1 and 28 days post
exposure (median diameter 33 nm). Smaller CeO2 NPs were detected 180 days post exposure
(median diameter 28 nm). Similar to the lung tissues, the mass recovery of Ce in 18–150 nm
CeO2 NPs (spICP-MS) in comparison to total Ce (ICP-MS) decreased from 66% ± 1 (1 day,
N = 3) to 13% ± 5 (180 days, N = 3) (Table 4). CeO2 NPs frequency in the liver tissue 1 day, 28
days and 180 days following intravenous injection and 180 days following intratracheal instil-
lation and normalized to % of recovery is presented in S6 Fig.
Fig 6. Mass percentage (%) of the total pulmonary dose of Ce or Ti in the liver 1 day, 28 days and 180 days after
intratracheal instillation. The calculation was based on a dose of 162 μg CeO2 or TiO2 NP per lung. Data are
presented as mean + SD.
https://doi.org/10.1371/journal.pone.0202477.g006
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The size distribution of the NPs that had translocated from lung to liver had a size distribu-
tion that was comparable to the size distribution of the IV dosed particles 180 days post-expo-
sure (Fig 8). Thus, the spICP-MS analyses demonstrated that the size of the CeO2 NPs lying
above the size LOD of the method decreased with time both in lung and liver tissue.
Discussion
Study concept
We studied liver deposition of CeO2 and TiO2 NPs over time following pulmonary exposure
in mice. NPs deposited in the lungs underwent extrapulmonary translocation and liver is one
Fig 7. Particle size distribution of CeO2 NPs in lung tissue 1 day (N = 6) and 180 days (N = 4) after intratracheal
instillation measured by spICP-MS. The distributions were normalized to the most frequently occurring size of the
distribution. The particle size distribution of CeO2 NP in the dosed suspension after enzymatic treatment is shown for
comparison.
https://doi.org/10.1371/journal.pone.0202477.g007
Table 3. Mass recovery of Ce in 18–150 nm CeO2 particles (determined by spICP-MS) compared to the total Ce
mass concentration (determined by ICP-MS) (%) and median particle diameters in the lungs 1 and 180 days post-
exposure.
Lungs Mass recovery of Ce as CeO2 NPs compared to total Ce (%) Median particle diameter (nm)
IT 1 day (N = 6) 40 ± 28 35 ± 3
IT 180 days
(N = 4)
6 ± 8 25 ± 1
Values are given as mean ± standard deviation. The presented particle diameters are mass-equivalent diameters.
https://doi.org/10.1371/journal.pone.0202477.t003
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of the major secondary organs for particles sequestration [21,55]. NPs may be cleared from the
lungs via mucociliary escalator resulting in subsequent oral exposure or may migrate across
the alveolar epithelium, through interstitium and gain access to the systemic circulation. We
show that pulmonary deposited CeO2 NPs were detected in the liver tissue 28 and 180 days
post exposure and TiO2 NPs were detected in the liver tissue 180 days post exposure as deter-
mined by darkfield imaging and by the quantification of Ce and Ti mass concentration by
ICP-MS. Darkfield imaging showed that the foreign material was predominantly found in
Fig 8. Particle size distribution of CeO2 NPs in liver tissue 1 day (N = 3), 28 days (N = 2), 180 days (N = 3) after
intravenous injection and 180 days (N = 5) after intratracheal instillation measured by spICP-MS. The size
distributions were normalized to the most frequently occurring size of the distribution. The particle size distribution of
CeO2 NPs in the dosed suspension after enzymatic treatment is shown for comparison.
https://doi.org/10.1371/journal.pone.0202477.g008
Table 4. Mass recovery of Ce in 18–150 nm CeO2 particles (determined by spICP-MS) compared to the total Ce
mass concentration (determined by ICP-MS) (%) and median particle diameters in the liver 1, 28 and 180 days
post-exposure.
Liver Mass recovery of Ce as CeO2 NPs compared to total Ce
(%)
Median particle diameter (nm)
IV 1day (N = 3) 66 ± 1 33 ± 1
IV 28 days (N = 2) 39 ± 4 33 ± 1
IV 180 days
(N = 3)
13 ± 5 28 ± 1
IT 180 days (N = 5) 13 ± 7 25 ± 1
Values are given as mean ± standard deviation. The presented particle diameters are mass-equivalent diameters.
https://doi.org/10.1371/journal.pone.0202477.t004
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sinusoids and often in close proximity to small nuclei, probably phagocytized by Kupffer cells.
Similarly, a previous study reported that IV dosed gold NPs accumulated in Kupffer cells in
the liver [29]. The lack of detection of NPs in the liver following oral gavage by either method
indicates that mucociliary clearance and subsequent uptake by the GI tract likely contributes
very little to the presence of NPs in the liver after intratracheal instillation. In agreement with
this, a recent biodistribution study of radioactively labelled TiO2 NPs reported that only 0.05%
of the orally dosed TiO2 NPs were retained in the body 7 days post-exposure [19]. The same
research group estimated that after pulmonary deposition of TiO2 NPs at least 80% of the par-
ticles that reached the liver had translocated from lung to systemic circulation whereas the
remaining 20% may have been taken up from the GI tract [16]. In agreement with this, TiO2
NPs have previously been detected in blood smears taken 24 hours after pulmonary exposure
[22].
Inhalation is a physiological route for exposure to NPs present in the ambient air, but we
decided to use intratracheal instillation since it allowed precise control of the administered
dose. In the present study, we exposed animals via three different routes. Therefore, it was
important to deliver the same dose regardless the administration method in order to be able to
compare results from different groups. The dose used in the present study is relevant for the
occupational exposure and corresponds to the pulmonary deposition occurring during thir-
teen 8-h working days at the Danish occupational exposure limit of 10 mg/m3 for TiO2, assum-
ing the same particle size distribution during aerosolization as that previously found for
similarly sized TiO2 NPs [45]. The TiO2 and CeO2 NPs were dosed by intratracheal instillation
as a model of inhaled particles. We used a previously established dispersion protocol to obtain
stable NP aggregates and agglomerates. NPs also form aggregates and agglomerates in air
[13,45], and thus, we believe that instillation can be used as a model of inhalation even though
the dose rate is very different. We used 2% serum in nanopure water as vehicle. The vehicle
was chosen based on the ability to form stable dispersions of small NP agglomerates, thus
allowing similar and correct dosing of all dosed animals. The spICP-MS analysis of the doses
suspension before and after enzymatic digestions confirms the agglomeration of NPs probably
due to the presence of the serum proteins (and which are then hydrolyzed by the protease).
After enzymatic digestion, primary particles and aggregates of very few particles must domi-
nate (median diameter 35 nm by spICP-MS vs. primary particle sizes of 13±12 nm). We have
previously shown that TiO2 NP-induced pulmonary inflammation was similar using pure
water or 2% serum as vehicle, indicating that the presence of serum did not influence the
observed inflammatory response [43]. Furthermore, inflammation was shown to depend on
deposited surface area independently of the agglomerate size of the dosed particles. The rates
of translocation of TiO2 NPs appeared comparable in the present study using intratracheal
instillation and in a previously published inhalation study [45]. In the previous study, mice
inhaled TiO2 NP (diameter 20 nm) for 11 consecutive days. Five days after end of exposure,
the lung concentration of Ti was 38 mg/kg corresponding to 38 000 ng/g [54], thus very similar
to the Ti concentrations found in lung tissue in the current study (S4 Fig). In the inhalation
study, the Ti content in liver tissue was 0.5 mg/kg, corresponding to 500 ng/g, 26–27 days
post-exposure. This is very similar to the findings in the current study, where the average Ti
content in the liver 28 days post-exposure was 542 ± 308 ng/g liver tissue (Fig 5B).
Extrapulmonary translocation of NPs
In the present study 180 days following pulmonary exposure, 2.87 ± 3.37% of the total lung-
delivered dose was found in the liver of mice intratracheally instilled with CeO2 NPs while
1.24 ± 1.98% of the total TiO2 dose translocated to the liver. The observed difference in the
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amount of NPs found in the liver was not statistically significant despite their difference in sol-
ubility [56] and their difference in shape (cubic in the case of CeO2 NPs and rod in the case of
TiO2 NPs).
Most studies [23,25,26,45,57] reported low rates (below 1%) of translocation of pulmonary
deposited insoluble NPs to secondary tissues [23]. The higher rates of translocation in the cur-
rent study might be related to the relatively long follow-up time of 180 days.
Rapid and significant translocation of inhaled ultrafine 13C particles (count median diame-
ter of 20–29 nm) into systemic circulation followed by subsequent deposition in liver was
observed [21]. Fisher 344 rats were exposed by 6 h whole-body inhalation to 80 or 180 μg/m3
of 13C NPs and liver burden was monitored up to 24 h following exposure. 13C NPs were
detected in the liver as early as 0.5 h post-inhalation. However, in our study we found no trans-
location of particles to the liver 24 h following exposure, but this may be caused by a higher
LOD in our method.
Absorption of NPs from the GIT
We found no absorption from the digestive tract neither of CeO2 nor of TiO2 following oral
gavage. These findings are consistent with other studies which have shown that NPs pass
through the GIT with no or negligible absorption and are eliminated rapidly via feces
[9,12,15,18,19,25,58,59].
In vivo-induced size transformation of CeO2 NPs
We have observed that the median mass-equivalent particle diameter decreased for the CeO2
NPs both in the liver and lung tissue 180 days post exposure as compared to 1 day post expo-
sure. A shift towards smaller particle size of IV-administered CeO2 NPs and increased reactive
surface area has been previously demonstrated and could be a possible explanation for our
observation [40]. The in vivo induced size transformation was observed in liver 90 days after
exposure resulting in formation of very small, 1–3 nm, ultrafine crystallites (called second-gen-
eration ceria particles). These small particles cannot be detected by spICP-MS. Here, we report
shifts in the size distribution (based on mass-equivalent diameters) of CeO2 NPs both in liver
and lung tissues. As a possible mechanism for the in vivo processing Graham et al. [40] sug-
gested partial dissolution of ceria in the liver promoted by the acidic environment of lyso-
somes. Since NPs are primarily found in macrophages in both liver and lung tissues [29,60], it
is very likely that the dissolution occurs intracellularly in the lysosomal structures.
Further studies should include (cryo)TEM investigations and systematic studies of CeO2
NPs in biological relevant media. The observed size distribution (based on mass-equivalent
diameters) of CeO2 NPs was similar for NPs dosed directly to the liver by IV dosing and the
NPs that had translocated from the lung. Particle translocation from lung has been shown to
be strongly size dependent [25,28]. However, given the similar size distribution of NPs in the
liver following IV and IT exposure, we were unable to determine whether dissolution of the
NPs in the lungs resulted in the translocation of the smaller particles or whether the translo-
cated primary particles underwent partial dissolution in the liver.
In the present study, both CeO2 NPs that underwent in vivo hepatic- and pulmonary-
induced changes of the mass-equivalent diameter and virtually insoluble TiO2 NPs accumu-
lated in liver over time following pulmonary exposure. Graham and co-workers have previ-
ously shown that Ce dissolved from CeO2 NPs recrystallized as 1–3 nm NPs, which is in the
size range that allows urinary excretion [40]. However, we have no indication that the rate of
accumulation of CeO2 NPs was lower than the accumulation of TiO2 NPs. Thus, the shift in
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size distribution towards smaller particles that took place both in lung and liver did not lead to
reduced liver accumulation.
Conclusions
The results of the present study indicate that pulmonary deposited CeO2 and TiO2 NPs are
translocated to the liver. The observed particle size distribution of CeO2 NPs indicated that
CeO2 NPs underwent in vivo processing in both lung and liver. There is no indication that the
partial dissolution in lungs and liver results in increased clearance of CeO2 NPs from the
organism. The results underscore that liver toxicity is an important endpoint when assessing
toxicity of NPs. It is important to establish whether the translocated NPs induce toxic effects in
extrapulmonary tissue.
Supporting information
S1 Fig. Particle size distribution of CeO2 NPs in the dosed suspension before and after
enzymatic treatment measured by spICP-MS. The distributions were normalized to the
most frequently occurring size of the distribution.
(TIF)
S2 Fig. STEM image of CeO2 NPs.
(TIF)
S3 Fig. Enhanced darkfield microscopy images of H&E stained liver tissue from orally
administered mice. (A) From mice that received a control vehicle, (B) 162 μg/animal of CeO2
or (C) TiO2 NPs 1 day (1) or 180 days (2) post exposure. No apparent foreign material was
detected.
(TIF)
S4 Fig. Content of Ce and Ti NPs in lung measured by ICP-MS following intratracheal
instillation. Data are presented as mean ± SD. Asterisks () denote P 0.01, () P 0.001,
() P 0.0001 in exposed groups compared to vehicle controls. Hashtag (#) denotes
P 0.05 and (##) P < 0.01 between Ce and Ti exposed groups.
(TIF)
S5 Fig. CeO2 nanoparticle frequency in lung tissue 1 day (N = 6) and 180 days (N = 4) after
intratracheal instillation measured by spICP-MS and normalized to % m/m recovery of
nanoparticles.
(TIF)
S6 Fig. CeO2 nanoparticles frequency in liver tissue 1 day (N = 3), 28 days (N = 2) and 180
days (n = 3) after intravenous injection and 180 days (N = 5) after intratracheal instillation
measured by spICP-MS and normalized to % m/m recovery of nanoparticles.
(TIF)
S1 Data. ICP-MS data for Ti in liver (Figs 5 and 6 in the manuscript).
(XLSX)
S2 Data. ICP-MS data for Ce in liver (Figs 5 and 6 in the manuscript).
(XLSX)
S3 Data. Data for spICP-MS diameters (Figs 7 and 8 in the manuscript).
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